The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Author [ Title(Desc)] Type Year
Filters: Author is Karagiannis, Asterios  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Karagiannis, A., Tziomalos K., Anagnostis P., Gossios T., & Athyros V. G. (2009).  Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?. Angiology. 60(4), 397-402.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Skaperdas A., Pagourelias E., et al. (2007).  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.. Lipids. 42(11), 999-1009.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Atorvastatin: safety and tolerability.. Expert Opin Drug Saf. 9(4), 667-74.
B
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention.. Curr Med Res Opin. 30(1), 55.
Loutradis, C., Papadopoulou E., Angeloudi E., Karagiannis A., & Sarafidis P. (2020).  The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.. Curr Med Chem. 27(39), 6682-6702.
Doumas, M., Stavropoulos K. V., Boutari C., Imprialos K. P., & Karagiannis A. (2017).  Blood pressure and cardiovascular outcomes: a closer look.. Lancet. 389(10076), 1295-1296.
Chimonas, T., Karagiannis A., Athyros V. G., Achimastos A., Elisaf M., & Panagiotakos D. B. (2010).  Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis.. Metab Syndr Relat Disord. 8(6), 523-9.
Athyros, V. G., Sachinidis A. G., Zografou I., Simoulidou E., Piperidou A., Stavropoulos N., et al. (2018).  Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.. Curr Pharm Des. 24(46), 5542-5547.
C
Pagourelias, E. D., Zorou P. G., Tsaligopoulos M., Athyros V. G., Karagiannis A., & Efthimiadis G. K. (2011).  Carbon dioxide balneotherapy and cardiovascular disease.. Int J Biometeorol. 55(5), 657-63.
Pagourelias, E. D., Koumaras C., Kakafika A. I., Tziomalos K., Zorou P. G., Athyros V. G., et al. (2009).  Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?. Angiology. 60(1), 74-81.
Athyros, V. G., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., & Mikhailidis D. P. (2015).  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World J Gastroenterol. 21(22), 6820-34.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2015).  Cardiovascular Risk in Middle East Populations: A Call to Action.. Angiology. 66(9), 801-2.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
Theocharidou, E., Gossios T. D., Giouleme O., Athyros V. G., & Karagiannis A. (2014).  Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review.. Angiology. 65(4), 284-93.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview.. Curr Vasc Pharmacol. 12(4), 627-41.
Athyros, V. G., Kakafika A., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opin Investig Drugs. 17(4), 445-9.
Athyros, V. G., Gossios T. D., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.. Arch Med Sci. 8(1), 6-10.
Anagnostis, P., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.. J Clin Endocrinol Metab. 94(8), 2692-701.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cold temperature and cardiovascular mortality.. Circ J. 77(11), 2846.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Anagnostis, P., Adamidou F., Slavakis A., Polyzos S. A., Selalmatzidou D., Panagiotou A., et al. (2014).  Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study.. Open Cardiovasc Med J. 8, 55-60.
Loutradis, C., Schoina M., Dimitroulas T., Doumas M., Garyfallos A., Karagiannis A., et al. (2020).  Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non-diabetic CKD.. J Clin Hypertens (Greenwich).
Athyros, V. G., Ganotakis E. S., Tziomalos K., Papageorgiou A. A., Anagnostis P., Griva T., et al. (2010).  Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population.. Curr Med Res Opin. 26(3), 713-9.
Karagiannis, A., Athyros V. G., & Mikhailidis D. P. (2009).  A comparison of the aldosterone-blocking agents eplerenone and spironolactone.. Clin Cardiol. 32(4), 230.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.